Cancer

Vanderbilt researchers have developed a new nanoparticle that can more effectively get drugs inside of cells to boost the immune system and fight diseases like cancer. Read More

A multidisciplinary research team at Vanderbilt University and Vanderbilt University Medical Center has discovered a new way to kill a tumor by disrupting its acidic “microenvironment” without harming normal tissue. Read More

A multidisciplinary team of investigators has received a 2023 Endeavor Award from The Mark Foundation for Cancer Research to support four closely linked projects exploring the fundamental mechanisms that drive the obesity-cancer connection, Read More

Chemical and biomedical engineer and cancer researcher Marjan Rafat has received the Young Innovator Award from the Cellular and Molecular Bioengineering division of the Biomedical Engineering Society. The CMBE Young Innovator Award is a distinguished honor for young faculty in the biomolecular engineering field. Read More

Vanderbilt's Center for Technology Transfer and Commercialization named Richard Caprioli, C. David Weaver, Susan Eagle, and Franz Baudenbacher 2023 Master Innovators. The yearly recognition program acknowledges Vanderbilt’s top innovators and entrepreneurs for their contributions to the creation, development, and commercialization of intellectual property. Read More

Vanderbilt engineering professor Justus Ndukaife is leading innovative research that more effectively traps nanosized extracellular vesicles and particles to analyze their roles in cancer, and neurodegenerative diseases. Read More

Vanderbilt researchers found that that T cells become “exhausted” within hours of encountering a tumor, challenging existing ideas about how T cells become dysfunctional. Read More

Vanderbilt researchers are bolstering the fight against cancer with technology that enhances the effectiveness of T cells that attack tumors. Read More

Fluorescent nanoparticles clearly identified colonic adenomas — precursors to colorectal cancer — in mice, and the formulation should translate to clinical use in humans. Read More

The laboratories of Brian Bachmann and Jonathan Irish have developed a method to discover new small molecules that may kill cancer cells by working through the body’s immune system. Read More

Vanderbilt reseach shows that resources for lung cancer screening programs increased the number of veterans screened. Read More

Ethan Lee, professor of cell and developmental biology and pharmacology, has been named a 2022 Innovation Fund investigator by The Pew Charitable Trusts.   Read More

Biomedical researchers open the door to new ways to detect cancer cells. Read More

Vanderbilt researchers have developed an active machine learning approach to predict the effects of tumor variants of unknown significance, or VUS, on sensitivity to chemotherapy. Characterizing VUS can maximize clinical care and precision medicine for each patient. Read More

Combining genetic testing with information from electronic health records revealed undiagnosed heart rhythm disorders and new conditions associated with inherited cancer gene mutations. Read More

A collaborative project between William Tansey and Stephen Fesik has laid the foundation for pre-clinical and clinical trials for rare childhood tumors that are diagnosed in 25 children per year in the United States. Read More

Ethan Zohn, winner of CBS’s "Survivor," a two-time cancer survivor, humanitarian and former professional soccer player, will discuss his journey with reality television, cancer, mental health and humanitarian work on April 26 at 7 p.m. CT at the Blair School’s Ingram Hall. Read More

Vanderbilt and the Salk Institute collaborate on the development of a research “road map” that could lead to new ways to detect early signs of tumor formation. Read More

The rigidity of the extracellular matrix that surrounds cells impacts the contractile and invasive properties of head and neck cancer cells. Read More

Melanoma is the fifth most-common type of cancer in the U.S., and according to the American Cancer Society, about half of patients with malignant melanoma have mutations of the BRAF gene. Identification of potential tumor biomarkers such as SOX10 can help physicians better predict outcomes for their patients.  Read More